University Medical Center Hamburg-Eppendorf-ko ikertzaileekin lankidetzan egindako argitalpenak (14)

2024

  1. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

    Blood, Vol. 144, Núm. 11, pp. 1193-1205

2023

  1. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

    Acta Neuropathologica, Vol. 145, Núm. 5, pp. 651-666

2022

  1. Hypersensitivity to Pegylated E.colia sparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group

    European Journal of Cancer, Vol. 162, pp. 65-75

2020

  1. Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis

    Journal of Clinical Immunology, Vol. 40, Núm. 6, pp. 901-916

  2. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: Results from the HLH-2004 study

    Blood Advances, Vol. 4, Núm. 15, pp. 3754-3766

2019

  1. A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis

    Cancer, Vol. 125, Núm. 6, pp. 963-971

2018

  1. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, Núm. 5, pp. 1508-1517

  2. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis

    Blood, Vol. 132, Núm. 19, pp. 2088-2096

2017

  1. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-Term results of the cooperative HLH-2004 study

    Blood, Vol. 130, Núm. 25, pp. 2728-2738

  2. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

    Journal of Pediatrics, Vol. 189, pp. 72-78.e3

2016

  1. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

    RMD Open, Vol. 2, Núm. 1

2015

  1. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood

    British Journal of Haematology, Vol. 169, Núm. 2, pp. 241-248

2013

  1. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years

    Pediatric Blood and Cancer, Vol. 60, Núm. 2, pp. 175-184

  2. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

    Blood, Vol. 121, Núm. 25, pp. 5006-5014